Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St stephen's hospital experience

Stambuk, Drago; Hawkins, David; Bg, Gazzard

doi:10.1016/s0163-4453(89)80079-9

Cited by 12 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In view of the small numbers of haemophiliacs with AIDS in each centre, and the difficulties of conducting controlled trials, there is a paucity of statistically significant data on the use of zidovudine in AIDS and ARC in this patient group. Table 4 is a summary of a literature search of the results of treatment of CDC IV patients with zidovudine Dournon et al 1988;Pinching et al 1989;Jones, 1989;Stambuk et al 1989;Williams et al 1989). The mortality figures (all under 20%), despite the considerable variety of studies, are remarkably similar.…”

Section: Discussionmentioning

confidence: 99%

Zidovudine treatment for anti-HIV positive haemophiliacs

Lim

Lee

Kernoff

2008

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Summary. Twenty haemophiliacs (17 CDC group IV and 3 CDC group II) were treated with zidovudine for a median of 37 weeks (range 10–66). Eight (40%) tolerated zidovudine without a dose change. Two patients died and five patients (29%) developed opportunist infections. Haematological toxicity occurred in ten CDC IV patients (59%) but only one case of sepsis occurred in 101 episodes of documented granulocytopenia. Thrombocytopenia responded to treatment with zidovudine in four of five patients. It is concluded that zidovudine is beneficial for symptomatic haemophiliacs and although the haematological toxicity is high, it is mostly asymptomatic, reversible and well tolerated. Two of the three CDC II patients treated with zidovudine progressed to CDC IV, but had low initial T4 lymphocyte counts and were P24 antigen positive.

show abstract

Section: Discussionmentioning

confidence: 99%

Zidovudine treatment for anti-HIV positive haemophiliacs

Lim

Lee

Kernoff

2008

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

show abstract

“…AZT has been clearly shown to prolong life and reduce symptoms in advanced HIV disease (Creagh-Kirk et al, 1988;Fischl et al, 1987Fischl et al, , 1989Fischl et al, , 1990Pinching et al, 1989;Stambuk, Hawkins, & Gazzard, 1989;Swanson & Cooper, 1990). Most recommendations also include treating patients who are symptomatic or who have rapidly falling CD4 counts with antiretrovirals (CDC, 1994a).…”

Section: When and Which Onementioning

confidence: 99%

Antiretroviral Therapy in Adults

Wise

1996

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

“…Too few patients who had never taken zidovudine remained under observation at 52 weeks to give a reliable comparative figure, but only 54% of this group survived to 36 weeks. 4.11 More recently, there have been a number of reports of the beneficial effect on the survival experience of people with AIDS after being treated with zidovudine (Dournon et al, 1988;Creagh-Kirk et al, 1988;Williams et al, 1989;Stambuk et al, 1989). Bach (1989) and Larder et al (1989Larder et al ( , 1989a have drawn attention to the limits of the efficacy of zidovudine when treatment is continued for a long period, suggesting that HIV becomes resistant to the drug after a while (Marx, 1989).…”

Section: With Aidsmentioning

confidence: 99%